Press Releases Brii Biosciences Limited

Stocks

2137

KYG1645A1094

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 04:08:30 2026-06-11 am EDT			5-day change	1st Jan Change
1.000 ^HKD	-3.85%		-7.41%	-29.08%

May. 27	Brii Biosciences Limited Presents Late-Breaking Data from Its Phase 2 Ensure Study At Easl Congress 2026	CI
May. 22	Brii Biosciences says arbitration between Brii and Vir remains in early stages with no resolution	RE

Press Releases

May. 27	Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV	PR
Mar. 19	Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results	PR
Nov. 07	Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine	PR
25-08-21	Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results	PR
25-07-03	Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China	PR
25-05-07	Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss	PR
25-03-30	Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification	PR
25-01-02	Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study	AQ
24-12-31	Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study	PR
24-11-20	Brii Bio Delivers First Head-to-Head Comparison of siRNA and PEG-IFN Combination versus PEG-IFN Alone at AASLD's The Liver Meeting 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA	AQ
24-06-07	Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024	PR
24-05-13	Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies	PR
24-03-05	Brii Biosciences Announces Agreements To Acquire VBI Vaccines' IP Rights In BRII-179	AQ
24-02-13	Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies	PR
24-01-03	Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer	PR
23-09-06	Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B	PR
23-08-22	Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results	PR
23-07-05	Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure	PR
23-07-05	Brii Biosciences Provides Latest Clinical Development and Corporate Updates	PR
23-06-25	Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693	PR
23-06-25	Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023	PR
23-05-31	Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders	PR
23-04-27	Brii Bio Publishes 2022 Environmental, Social and Governance Report	PR
22-10-19	Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022	PR
22-09-26	Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression	PR